Kansen Bio

Kansen Biopharma is a clinical-stage biotechnology company headquartered in Suzhou, China, focused on developing breakthrough small molecule therapies for infectious diseases and oncology. The company's primary focus is on achieving a functional cure for chronic hepatitis B (CHB) through its lead candidate, KS-001, a potent HBV capsid assembly modulator. Kansen utilizes a proprietary drug discovery platform to identify novel chemical entities that target critical stages of viral replication. With a team of experienced industry veterans, the company aims to address significant unmet medical needs in the global antiviral market. The firm is backed by prominent venture capital firms and operates out of the Suzhou Biobay industrial park.